An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Roche logo

Roche

Status

Completed

Conditions

Pancreatic Cancer

Treatments

Drug: gemcitabine
Drug: erlotinib

Study type

Observational

Funder types

Industry

Identifiers

NCT01782690
ML23024

Details and patient eligibility

About

This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed. Data will be collected for 12 months.

Enrollment

338 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults, age >= 18 years
  • Patients with metastatic pancreatic cancer where investigators have decided to give combination therapy of erlotinib and gemcitabine according to Summary of Product Characteristics (SmPC)

Exclusion criteria

  • Contraindications for erlotinib according to Summary of Products Characteristics (SmPC)

Trial design

338 participants in 1 patient group

Erlotinib plus Gemcitabine
Description:
Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.
Treatment:
Drug: gemcitabine
Drug: erlotinib

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems